Medical News Today -
12 Nov 2013 12:00
Breast cancers that initially respond to hormone therapies such as tamoxifen eventually become resistant to treatment, and a new study finds this may be because of a mutation in the receptor present in the cancer cell to which tamoxifen binds, according to data published in Cancer Research, a journal of the American Association for Cancer Research. "Virtually all patients with metastatic breast cancer who initially respond to endocrine [hormone] treatments eventually develop resistance to these ...
Share this Article